Advertisement

Systemic Sclerosis (Scleroderma)

  • Lazaros I. SakkasEmail author
Chapter

Abstract

Systemic sclerosis (SSc) is a rare systemic chronic disease characterized by widespread fibrosis of skin and internal organs, microvasculopathy, and autoantibodies that frequently affects internal organs and quality of life and survival. Disease-related autoantibodies, anti-topoisomerase I, anticentromere, and anti-RNA polymerase III antibodies, Raynaud’s phenomenon, and microvasculopathy, as detected by nailfold capillaroscopy, appear before skin fibrosis and help in early diagnosis. Based on the extent of skin involvement, SSc is divided into limited cutaneous SSc and diffuse cutaneous SSc. SSc-related autoantibodies are associated with manifestations and help in the management of SSc patients. In this chapter we review epidemiology, pathogenesis, clinical manifestations, specific organ involvement and assessment tools, diagnosis, differential diagnosis, and treatment.

Keywords

Autoantibodies Differential diagnosis Manifestations Pulmonary arterial hypertension Systemic sclerosis Treatment 

References

  1. 1.
    Royle JG, et al. The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink. Clin Rheumatol. 2018;37(8):2103–11.CrossRefGoogle Scholar
  2. 2.
    Meier FM, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2012;71(8):1355–60.CrossRefGoogle Scholar
  3. 3.
    Morgan ND, et al. Clinical and serological features of systemic sclerosis in a multicenter African American cohort: analysis of the genome research in African American scleroderma patients clinical database. Medicine (Baltimore). 2017;96(51):e8980.CrossRefGoogle Scholar
  4. 4.
    Marangoni RG, et al. Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors. Arthritis Rheumatol. 2015;67(4):1062–73.CrossRefGoogle Scholar
  5. 5.
    Sakkas LI, Chikanza IC, Platsoucas CD. Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol. 2006;2(12):679–85.CrossRefGoogle Scholar
  6. 6.
    Sakkas LI, Bogdanos DP. Systemic sclerosis: new evidence re-enforces the role of B cells. Autoimmun Rev. 2016;15(2):155–61.CrossRefGoogle Scholar
  7. 7.
    Bhattacharyya S, et al. Tenascin-C drives persistence of organ fibrosis. Nat Commun. 2016;7:11703.CrossRefGoogle Scholar
  8. 8.
    Dore A, et al. Significance of palpable tendon friction rubs in early diffuse cutaneous systemic sclerosis. Arthritis Care Res (Hoboken). 2013;65(8):1385–9.CrossRefGoogle Scholar
  9. 9.
    Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–99.CrossRefGoogle Scholar
  10. 10.
    Bussone G, Mouthon L. Interstitial lung disease in systemic sclerosis. Autoimmun Rev. 2011;10(5):248–55.CrossRefGoogle Scholar
  11. 11.
    Goh NS, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177(11):1248–54.CrossRefGoogle Scholar
  12. 12.
    Coghlan JG, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73(7):1340–9.CrossRefGoogle Scholar
  13. 13.
    Galie N, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119.CrossRefGoogle Scholar
  14. 14.
    Kylhammar D, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2017;39(47):4175–81.CrossRefGoogle Scholar
  15. 15.
    Chung L, et al. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken). 2014;66(3):489–95.CrossRefGoogle Scholar
  16. 16.
    Sakkas LI, et al. Intestinal involvement in systemic sclerosis: a clinical review. Dig Dis Sci. 2018;63(4):834–44.CrossRefGoogle Scholar
  17. 17.
    Guillevin L, et al. Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology (Oxford). 2012;51(3):460–7.CrossRefGoogle Scholar
  18. 18.
    van den Hoogen F, et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–55.CrossRefGoogle Scholar
  19. 19.
    Lazzaroni MG, et al. Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening. J Rheumatol. 2017;44(5):639–47.CrossRefGoogle Scholar
  20. 20.
    Valentini G, et al. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis. 2017;76(1):270–6.CrossRefGoogle Scholar
  21. 21.
    Tyndall A, Fistarol S. The differential diagnosis of systemic sclerosis. Curr Opin Rheumatol. 2013;25(6):692–9.CrossRefGoogle Scholar
  22. 22.
    Wigley F, et al. Case records of the Massachusetts General Hospital. Case 8-2015. A 68-year-old man with multiple myeloma, skin tightness, arthralgias, and edema. N Engl J Med. 2015;372(11):1056–67.CrossRefGoogle Scholar
  23. 23.
    Hao Y, et al. Early mortality in a multinational systemic sclerosis inception cohort. Arthritis Rheumatol. 2017;69(5):1067–77.CrossRefGoogle Scholar
  24. 24.
    Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis. 2007;66(7):940–4.CrossRefGoogle Scholar
  25. 25.
    Shah AA, et al. Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma. Arthritis Rheumatol. 2015;67(4):1053–61.CrossRefGoogle Scholar
  26. 26.
    Kowal-Bielecka O, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–39.CrossRefGoogle Scholar
  27. 27.
    Fernandez-Codina A, Walker KM, Pope JE. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. 2018;70(11):1820–8.CrossRefGoogle Scholar
  28. 28.
    Herrick AL, et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis. 2017;76(7):1207–18.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health SciencesUniversity of ThessalyLarissaGreece

Personalised recommendations